Table 1.
Published intragenic CNVs in SPAST of size >30 bp.
No. | Exon(s) Involved |
Clinical Diagnosis (No. different families if >1) |
Method of Detection |
Coordinatesa | Reference |
---|---|---|---|---|---|
Deletions | |||||
1 | 1 | AD-HSP | MLPA | - | 15 |
2 | 1 | AD-HSPb (3 families) |
MLPA | - | 12 |
3 | 1 | HSP | MLPA | - | 14 |
4 | 1 | AD-HSP (1 or 2 families) |
MLPA | - | 17 |
5 | 1 (partial) |
AD-HSP | Southern blot, seq |
Chr2:32,142,293 −32,144,598 |
31 |
6 | 1–3 | AD-HSP | MLPA | - | 15 |
7 | 1–3 | HSP | MLPA | - | 16 |
8 | 1–4 | AD-HSPb | MLPA | - | 12 |
9 | 1–7 | AD-HSP | MLPA | - | 15 |
10 | 1–17 | AD-HSPb (4 families) |
MLPA | - | 12 |
11 | 2–5 | AD-HSP | MLPA | - | 15 |
12 | 2–9 | Familial HSP | MLPA | - | 16 |
13 | 2–16 | AD-HSP | MLPA | - | 49 |
14 | 2–16 | Familial HSP | MLPA | - | 16 |
15 | 2–17 | HSP | MLPA | - | 14 |
16 | 3–17 | Spastic paraplegia | MLPA | - | 50 |
17 | 4 | HSP | MLPA | - | 50 |
18 | 4–17 | AD-HSP | MLPA | - | 49 |
19 | 4–17 | AD-HSPb | MLPA | - | 12 |
20 | 5 | HSP | MLPA | - | 14 |
21 | 5–6 | AD-HSPb | MLPA | - | 12 |
22 | 5–7 | AD-HSP | MLPA | - | 15 |
23 | 5–7 | AD-HSPb | MLPA | - | 12 |
24 | 5–15 | AD-HSP (2 families) |
MLPA | - | 15 |
25 | 6 | AD-HSPb | MLPA | - | 12 |
26 | 6–17 | AD-HSP | MLPA | - | 15 |
27 | 8 | Familial HSP | MLPA | - | 16 |
28 | 8–9 | AD-HSP | MLPA | - | 17 |
29 | 8–12 | AD-HSPb | MLPA | - | 12 |
30 | 8–17 | AD-HSP | MLPA | - | 49 |
31 | 8–17 | AD-HSPb (2 families) |
MLPA | - | 12 |
32 | 9 | AD-HSPb | MLPA | - | 12 |
33 | 9–12 | AD-HSPb | MLPA | - | 12 |
34 | 9–17 | Familial HSP | MLPA | - | 16 |
35 | 10 | AD-HSP | MLPA | - | 15 |
36 | 10–12 | AD-HSP | MLPA | - | 15 |
37 | 10–12 | AD-HSP | MLPA | - | 49 |
38 | 10–12 | HSP | MLPA | - | 14 |
39 | 10–12 | AD-HSP | MLPA | - | 51 |
40 | 10–16 | AD-HSPb | MLPA | - | 12 |
41 | 10–16 | Familial HSP | MLPA | - | 52 |
42 | 13 | AD-HSPb (2 families) |
MLPA | - | 12 |
43 | 13–16 | HSP | PCR and electrophoresis of cDNA |
- | 5 |
44 | 14–17 | Spastic paraplegia | MLPA | - | 50 |
45 | 16 | AD-HSP | MLPA | - | 49 |
46 | 16 | AD-HSPb (2 families) |
MLPA | - | 12 |
47 | 16–17 | AD-HSP | MLPA | - | 15 |
48 | 16–17 | AD-HSPb | MLPA | - | 12 |
49 | 17 | AD-HSP | MLPA | - | 15 |
50 | 17 | AD-HSP (2 families) |
MLPA | - | 49 |
51 | 17 | AD-HSPb | MLPA | - | 12 |
52 | 17 | HSP | MLPA | - | 16 |
53 | 17 | Sporadic spastic paraplegia |
MLPA | - | 51 |
54 | 17 | HSPc |
MLPA, LS- aCGH, seq |
See text and figures |
Present Investigation (Patient A37) |
55 | 17 | HSPc |
MLPA, LS- aCGH, seq |
See text and figures |
Present Investigation (Patient A39) |
Duplication | |||||
56 | 10–12 | AD-HSP | MLPA, seq | Chr2:32,212,239 −32,216,284 |
6 |
Complex | |||||
57 | 17 | HSPc |
MLPA, LS- aCGH, seq |
See text and figures |
Present Investigation (Patient A38) |
March 2006 assembly of the reference genome (NCBI36/hg18).
One of 121 families studied by Depienne et al.12 displayed disease in two siblings, rather than strict AD inheritance. It is unclear whether this family is represented by any exonic CNV reported in the table.
Inheritance is not known for these anonymized samples.
AD, autosomal dominant; HSP, hereditary spastic paraplegia; MLPA, multiplex ligation-dependent probe amplification; LS-aCGH, locus-specific aCGH; seq, DNA sequencing.